Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 10:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–10 of 10 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Epidermal Nevus Syndrome Clear all
Active, not recruiting Not applicable Interventional
View directory record Official record
Conditions
Chronic Venous Insufficiency, CVI, Venous Malformations, Venous Leg Ulcers, Klippel-Trenaunay Syndrome, CLOVES Syndrome, Blue Rubber Bleb Nevus Syndrome
Interventions
High Intensity focused ultrasound
Device
Lead sponsor
Sonablate
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Darien, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced May 21, 2026, 10:57 PM EDT
Not listed Early Phase 1 Interventional
View directory record Official record
Conditions
Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS), Epidermal Nevus Syndrome
Interventions
Burosumab
Drug
Lead sponsor
Laura Tosi
Other
Eligibility
Not listed
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 6, 2022 · Synced May 21, 2026, 10:57 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
BNT326, Pumitamig, Itraconazole, Paroxetine
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
980 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
15
States / cities
San Francisco, California • Hartford, Connecticut • New Haven, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced May 21, 2026, 10:57 PM EDT
Withdrawn Phase 2 Interventional
View directory record Official record
Conditions
Epidermal Nevi, Nevus Sebaceus
Interventions
NFX-179 Gel 1.50%
Drug
Lead sponsor
Albert Chiou
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated May 27, 2024 · Synced May 21, 2026, 10:57 PM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Vascular Anomaly, Generalized Lymphatic Anomaly, Kaposiform Hemangioendothelioma, Kaposiform Lymphangiomatosis, Gorham-Stout Disease, Klippel Trenaunay Syndrome, Congenital Lipomatous Overgrowth, Vascular Malformations, and Epidermal Nevi
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Day and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2050
U.S. locations
2
States / cities
Boston, Massachusetts • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced May 21, 2026, 10:57 PM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Lymphatic Malformation, Generalized Lymphatic Anomaly (GLA), Central Conducting Lymphatic Anomaly, CLOVES Syndrome, Gorham-Stout Disease ("Disappearing Bone Disease"), Blue Rubber Bleb Nevus Syndrome, Kaposiform Lymphangiomatosis, Kaposiform Hemangioendothelioma/Tufted Angioma, Klippel-Trenaunay Syndrome, Lymphangiomatosis
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2035
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced May 21, 2026, 10:57 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Tumor Induced Osteomalacia (TIO), Epidermal Nevus Syndrome (ENS)
Interventions
Burosumab
Biological
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
7
States / cities
Golden, Colorado • New Haven, Connecticut • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated May 5, 2024 · Synced May 21, 2026, 10:57 PM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Hypophosphatemia, Hypophosphatemic Rickets, Pain, Chronic
Interventions
Burosumab
Biological
Lead sponsor
Redwood Dermatology Sciences
Other
Eligibility
Up to 18 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Clinton, Utah
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced May 21, 2026, 10:57 PM EDT
Completed Phase 4 Interventional Results available
View directory record Official record
Conditions
Epidermal Nevus Syndrome
Interventions
Crysvita (burosumab-twza) Treatment
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
6 Months and older · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced May 21, 2026, 10:57 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
PIK3CA-Related Overgrowth Spectrum (PROS), Lymphatic Malformations, Vascular Malformations, PIK3CA Mutation, CLOVES Syndrome, Klippel Trenaunay Syndrome, Megalencephaly-capillary Malformation Polymicrogyria Syndrome (MCAP)
Interventions
RLY-2608, Placebo
Drug
Lead sponsor
Relay Therapeutics, Inc.
Industry
Eligibility
2 Years and older
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
19
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced May 21, 2026, 10:57 PM EDT